Neonatal Drug Withdrawal Risk Up with In Utero Exposure to Opioids, Psychotropics

Risk of withdrawal increased two-fold with in utero exposure to 2 or more psychotropics plus opioids
Risk of withdrawal increased two-fold with in utero exposure to 2 or more psychotropics plus opioids

HealthDay News — Use of psychotropic medications in addition to prescription opioids during pregnancy is associated with increased risk and severity of neonatal drug withdrawal, according to a study published online August 2 in The BMJ.

Krista F. Huybrechts, PhD, from Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues conducted an observational cohort study involving 201,275 pregnant women with public insurance who were exposed to opioids around the time of delivery and their liveborn infants. 

Related Articles

The researchers observed variation in the absolute risk for neonatal drug withdrawal from 1.0 to 11.4% for infants exposed in utero to prescription opioids alone and opioids co-prescribed with gabapentin, respectively. Among neonates exposed in utero to prescription opioids, the propensity score-adjusted relative risk was 1.34 (95% confidence interval [CI], 1.22 to 1.47) with concomitant exposure to antidepressants, 1.49 (95% confidence interval, 1.35 to 1.63) with benzodiazepines, 1.61 (95% CI, 1.26 to 2.06) with gabapentin, 1.20 (95% CI, 0.95 to 1.51) with antipsychotics, and 1.01 (95% CI, 0.88 to 1.15) with non-benzodiazepine hypnotics (Z-drugs). The risk of withdrawal was increased two-fold with in utero exposure to two or more psychotropic medications along with opioids (2.05; 95% CI, 1.77 to 2.37).

"The current findings suggest that these drugs could further increase the risk and severity of neonatal drug withdrawal," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text
Editorial